Potential effect of olanzapine on total antioxidant status and lipid peroxidation in schizophrenic patients

Neuropsychobiology

Volumn 59, Issue 1, 2009, Pages 8-11

  Al Chalabi, Basil M ^a   Thanoon, Imad A J ^a   Ahmed, Faris A ^a  

^a UNIVERSITY OF MOSUL   (Iraq)

Author keywords

Antipsychotics; Olanzapine; Schizophrenia

Indexed keywords

MALONALDEHYDE; OLANZAPINE;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; LIPID PEROXIDATION; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIOXIDANTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; HUMANS; LIPID PEROXIDATION; MALONDIALDEHYDE; SCHIZOPHRENIA; YOUNG ADULT;

EID: 60049100913     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000202823     Document Type: Article

References (23)

1. Mahadik SP, Mukherjee S, Scheffer R, Correnti EE, Mahadi JS: Elevated plasma lipid peroxides at the onset of non-affective psychosis. Biol Psychiatry 1998;43:674-679.
2. Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N: Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct 2002;20:171-175.
3. Dakhale G, Khanzode S, Khanzode S, Saoji A, Khobragade L, Turankar A: Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics. Neuropsychobiology 2004;49:205-209.
4. Akyol O, Herken H, Uz E, Fadillioglu E, Unal S, Sogut S, Ozyurt H, Savas HA: The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients: the possible role of oxidant/antioxidant imbalance. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:995-1005.
5. Zhang XY, Tan YL, Cao LY, Wu GY, Xu Q, Shen Y, Zhou DF: Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr Res 2006;81: 291-300.
6. Glazov VA, Mamtesev VP: Catalase in the blood and leukocytes of patients with nuclear schizophrenia. Zh Nevropatol Psikhiatr Im S S Korsakova 1976;76:549-552.
7. Hale AS: Olanzapine. Br J Hosp Med 1997; 58:442-445.
8. Lund BC, Perry PJ: Olanzapine: an atypical antipsychotic for schizophrenia. Expert Opin Pharmacother 2000;2:305-323.
9. Kropp S, Kern V, Lange K, Degner D, Hajak G, Kornhuber J, Ruther E, Emrich HM, Schneider U, Bleich S: Oxidative stress during treatment with first- and second- generation antipsychotics. J Neuropsychiatry Clin Neurosci 2005;17:227-231.
10. Parikh V, Khan MM, Mahadik SP: Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatr Res 2003;37:43-51.
11. Pillai A, Parikh V, Terry AV, Mahadik SP: Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatr Res 2007;41:372-386.
12. Yao JK, Reddy R, McElhinny LG, van Kammen DP: Reduced status of plasma total antioxidant capacity in schizophrenia. Schizoph Res 1998;32:1-8.
13. Miller NJ, Rice-Evans C, Davies MJ, Gopinathan V, Milner A: A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci 1993;84:407-412.
14. Buege JA, Aust SD: Microsomal lipid peroxidation. Meth Enzymol 1978;52:302-310.
15. Rachkauskas GS: The level of lipid peroxidation and the function of the antioxidant system in different forms of schizophrenia. Lik Sprava 1998;5:92-93.
16. Masserano JM, Baker I, Venable D, Gong L, Zullo SJ, Merril CR, Wyatt RH: Dopamine induces cell death, lipid peroxidation and DNA base damage in a catecholaminergic cell line derived from the central nervous system. Neurotox Res 2000;1:171-179.
17. Jacob RA: The integrated antioxidant system. Nutr Res 1995;15:755-766.
18. Abdalla DS, Monteiro HP, Oliveira JA, Bechara EJ: Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic-depressive patients. Clin Chem 1986;32:805-807.
19. Martins NR, Petronilho FC, Gomes KM, Dal-Pizzol F, Streck EL, Quevedo J: Antipsychotic-induced oxidative stress in rat brain. Neurotox Res 2008;13:63-69.
20. Bai O, Wei Z, Lu W, Bowen R, Keegan D, Li XM: Protective effects of atypical antipsychotic drugs on PC12 cells after serum withdrawal. J Neurosci Res 2002;69:278-283.
21. 2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001;158:360-369.
22. Papas AM: Determinants of antioxidant status in humans. Lipids 1996;31:S77-S82.
23. Dakhale GN, Khanzode SD, Khanzode SS, Saoji A: Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia. Psychopharmacology 2005;182: 494-498.